VEGFA and nonpapillary renal cell carcinoma: Our data provide support for combining anti-angiogenic therapies to achieve a more effective treatment response; and specifically warrant clinical investigation of anti-Dll4 therapies alone and in combination with VEGF targeting agents for the treatment of ccRCC.